PKI News and Press, PerkinElmer Inc. From 03/01/22

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Cowen 42 nd Annual Health Care Conference and the Barclays Global Healthcare Conference. Cowen 42nd Annual Health Care Conferenc...

PerkinElmer has seen a real boom on the back of the pandemic. With the pandemic fading, PerkinElmer is facing some headwinds as the ¨organic¨ performance remains impressive. Given these developments, I am happy to continue to hold onto my long position, as I see no reaso...

PerkinElmer posted better-than-expected results in Q4'21, with both COVID-19 and core businesses exceeding expectations. I believe management has been opportunistic with the COVID-19 windfall, reinvesting in M&A to better position the company for growth in areas like cytometry, ce...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at Citi’s 2022 Virtual Healthcare Conference on Thursday, February 24, 2022 at 8:45 a.m. ET. Prahlad Singh, president and chief exec...

Shares of PerkinElmer (NYSE: PKI) fell 14.4% in January, according to data from from S&P Global Market Intelligence . The company specializes in medical diagnostic, food, environmental, and industrial testing, plus life science research. The stock closed at $201.06 on Dec. 3...

EUROIMMUN assay used to detect previous dengue virus infection will help children and adolescents gain access to vaccine EUROIMMUN , a PerkinElmer, Inc. (NYSE:PKI) company, today announced that its EUROIMMUN® Anti-Dengue Virus NS1 Type 1-4 ELISA (IgG) (research ...

PerkinElmer, Inc. (PKI) Q4 2021 Earnings Conference Call February 01, 2022 5:00 PM ET Company Participants Steve Willoughby – Vice President of Investor Relations Prahlad Singh – President and Chief Executive Officer Jamey Mock – Senior Vice President and Chief Financial ...

A nice beat on the both the top and bottom lines in Q4 2021 isn't having an impact on PerkinElmer (NYSE:PKI) shares in post-market trading. They are unchanged. In the quarter, the company's discovery and analytical solutions segment saw revenues rise 30% to $655M year-over-year. However,...